# Accretion / Dilution Analysis in M&A *Alex Tapio · 2026-06-17 · 13 min · Model Deep-Dives* Canonical: https://finamodel.com/blog/accretion-dilution-analysis Learn accretion / dilution analysis in M&A: the P/E rule of thumb, pro forma EPS mechanics, a full worked example across cash, stock, and mixed financing, plus synergies and breakeven analysis. **Accretion / dilution analysis answers the first question every M&A banker is asked about a deal: will it raise or lower the acquirer's earnings per share? An *accretive* deal lifts pro forma EPS above the acquirer's standalone EPS; a *dilutive* deal drops it below. This guide explains the mechanics, the famous P/E rule of thumb, a full worked example across cash, stock, and mixed financing, how synergies and breakeven analysis fit in, and the mistakes that quietly break most accretion / dilution models.** Accretion / dilution is the back-of-the-envelope test that gets run on every deal before anyone builds a full merger model. It is deceptively simple: combine the two companies' earnings, adjust for how the deal is paid for, divide by the new share count, and compare the result to the acquirer's standalone EPS. Yet it drives boardroom decisions, because public-company acquirers are judged on EPS, and an EPS-dilutive deal is a hard story to sell to shareholders. The catch is that "accretive" and "value-creating" are not the same thing. A deal can be accretive and still destroy value (cheap debt funding a poor business), or dilutive and still create enormous value (think early-stage, high-growth targets). Accretion / dilution measures the *near-term EPS optics*, not the economics. Understanding exactly what it does and does not say is what separates a useful analysis from a misleading one. ```mermaid flowchart TD A["Combine Acquirer and Target Net Income"] --> B["Adjust for Financing Costs"] B --> C["Add After-Tax Synergies"] C --> D["Compute Pro Forma EPS"] D --> E{"Pro Forma EPS vs Standalone EPS"} E -->|Higher EPS| F["Accretive deal"] E -->|Lower EPS| G["Dilutive deal"] E -->|Equal| H["Breakeven"] ``` *The Accretion / Dilution Workflow: from combined earnings to a pro forma EPS verdict.* --- ## What Accretion / Dilution Actually Measures The entire analysis reduces to one comparison: ``` Accretion / (Dilution) % = Pro Forma EPS / Standalone Acquirer EPS - 1 ``` Where pro forma EPS is the combined company's earnings per share *after* the deal closes: ``` Pro Forma EPS = Pro Forma Net Income / Pro Forma Diluted Shares ``` A positive result means the deal is **accretive**; a negative result means **dilutive**; zero is **breakeven**. Everything else in the model exists to build up those two numbers - pro forma net income and pro forma shares - correctly. **Pro forma net income** starts with the two companies' standalone net incomes and then layers on the earnings consequences of *how the deal is financed and integrated*: ``` Pro Forma Net Income = Acquirer Net Income + Target Net Income + After-Tax Synergies - After-Tax Interest on New Acquisition Debt - After-Tax Foregone Interest on Cash Used - After-Tax Incremental D&A from Asset Write-Ups ``` **Pro forma shares** is the acquirer's diluted share count plus any new shares issued to fund a stock-financed portion of the deal: ``` Pro Forma Diluted Shares = Acquirer Diluted Shares + New Shares Issued ``` The three financing levers - new debt, balance-sheet cash, and new equity - each hit the equation differently. Debt and cash reduce net income (interest cost, foregone interest); equity increases the share count. Which lever you pull is usually the single biggest driver of the result. --- ## The P/E Rule of Thumb Before building anything, you can predict the direction of a **100% stock** deal with a single comparison: the acquirer's P/E versus the P/E it is paying for the target (inclusive of the control premium). | Comparison | All-Stock Result | | :--- | :--- | | Acquirer P/E **>** P/E Paid | **Accretive** | | Acquirer P/E **<** P/E Paid | **Dilutive** | | Acquirer P/E **=** P/E Paid | Breakeven | The intuition: in an all-stock deal the acquirer is effectively "printing" its own equity - valued at its P/E - to buy the target's earnings at the P/E it pays. Buy earnings more cheaply than your own stock is valued, and EPS goes up. The "P/E paid" is the *effective deal multiple*, which includes the premium: ``` P/E Paid = Offer Value for Equity / Target Net Income ``` For **cash deals** the comparison shifts: instead of the acquirer's P/E, you compare the target's earnings yield (1 ÷ P/E paid) against the after-tax cost of the cash or debt used. If the target's earnings buy more than the after-tax financing costs, the deal is accretive. Because after-tax debt is usually far cheaper than equity, cash deals are almost always *more* accretive than the same deal done in stock - which is exactly why so many strategic buyers reach for debt first. The P/E multiples you plug in here are the same ones you would pull from a [comparable company analysis](/blog/comparable-company-analysis). The live model below shows where those trading multiples come from before they feed the deal math. --- ## Worked Example: BuyCo Acquires SellCo Let's run the numbers on a concrete deal. Two standalone profiles: | Metric | BuyCo (Acquirer) | SellCo (Target) | | :--- | :---: | :---: | | Net Income | $500.0M | $120.0M | | Diluted Shares | 250.0M | 60.0M | | **EPS** | **$2.00** | **$2.00** | | Share Price | $40.00 | $30.00 | | **P/E** | **20.0x** | **15.0x** | | Market Cap | $10,000M | $1,800M | **Deal terms:** BuyCo offers **$36.00 per share** for SellCo - a 20% premium to the $30.00 unaffected price. ```excel // Equity offer value (what BuyCo pays SellCo shareholders) = Offer_Price_Per_Share * Target_Shares = 36.00 * 60.0 // = $2,160M // Effective P/E paid (includes the 20% premium) = Offer_Value / Target_Net_Income = 2160 / 120 // = 18.0x ``` So BuyCo is paying **18.0x** earnings - above SellCo's standalone 15.0x because of the premium, but still below BuyCo's own **20.0x**. The rule of thumb already tells us an all-stock deal will be *accretive*. Assume a **25% tax rate** and that any cash portion is funded with **new debt at 6.0%**. ### Scenario A - 100% Cash (debt-financed) ```excel // New acquisition debt = full offer value New_Debt = 2160 // After-tax interest cost = New_Debt * Interest_Rate * (1 - Tax_Rate) = 2160 * 0.06 * 0.75 // = $97.2M // Pro forma net income (no new shares) = 500 + 120 - 97.2 // = $522.8M // Pro forma EPS = 522.8 / 250 // = $2.091 ``` Accretion = $2.091 / $2.00 − 1 = **+4.6%**. ### Scenario B - 100% Stock ```excel // New shares issued at BuyCo's $40 price = Offer_Value / Acquirer_Share_Price = 2160 / 40 // = 54.0M new shares // Pro forma shares = 250 + 54 // = 304.0M // Pro forma net income (no financing cost) = 500 + 120 // = $620.0M // Pro forma EPS = 620 / 304 // = $2.040 ``` Accretion = $2.040 / $2.00 − 1 = **+2.0%**. ### Scenario C - 50% Cash / 50% Stock Half the $2,160M is debt ($1,080M → $48.6M after-tax interest); half is stock ($1,080M ÷ $40 = 27.0M new shares). ```excel // Pro forma net income = 500 + 120 - (1080 * 0.06 * 0.75) // = $571.4M // Pro forma shares = 250 + (1080 / 40) // = 277.0M // Pro forma EPS = 571.4 / 277 // = $2.063 ``` Accretion = $2.063 / $2.00 − 1 = **+3.1%**. ### Comparing the Three Structures | Financing | Pro Forma Net Income | Pro Forma Shares | Pro Forma EPS | Accretion / (Dilution) | | :--- | :---: | :---: | :---: | :---: | | 100% Cash (debt) | $522.8M | 250.0M | $2.091 | **+4.6%** | | 50% / 50% | $571.4M | 277.0M | $2.063 | **+3.1%** | | 100% Stock | $620.0M | 304.0M | $2.040 | **+2.0%** | All three are accretive, but **cash is the most accretive**. The after-tax cost of debt is 6.0% × (1 − 25%) = **4.5%**, while BuyCo buys SellCo's earnings at an 18.0x multiple - a 5.6% earnings yield. Funding a 5.6% yield with 4.5% money is pure accretion. The all-stock structure is thinnest because BuyCo issues equity valued at a 5.0% earnings yield (1 ÷ 20.0x) to buy earnings yielding 5.6% - still positive, but a narrower spread. --- ## Layering in Synergies Synergies - cost savings or revenue gains from combining the businesses - are added to pro forma net income on an **after-tax** basis. Take the all-stock deal (the thinnest at +2.0%) and assume BuyCo can extract **$50M of annual pre-tax cost synergies**: ```excel // After-tax synergies = Pretax_Synergies * (1 - Tax_Rate) = 50 * 0.75 // = $37.5M // Pro forma net income with synergies = 620 + 37.5 // = $657.5M // Pro forma EPS = 657.5 / 304 // = $2.163 ``` Accretion jumps from +2.0% to **+8.1%**. Synergies are frequently the difference between a dilutive headline and an accretive one - which is also why they get scrutinised heavily. A model that only "works" with aggressive, unsubstantiated synergies is a red flag, not a green light. --- ## Breakeven Analysis: How Much Synergy Do You Need? When a deal is dilutive, the most useful number you can produce is the **breakeven synergies** - the amount of pre-tax synergy required to push pro forma EPS back to the acquirer's standalone EPS. Suppose BuyCo had to pay up: a **40% premium**, or **$42.00 per share**. ```excel // Offer value and P/E paid = 42 * 60 // = $2,520M = 2520 / 120 // = 21.0x (above BuyCo's 20.0x -> dilutive) // All-stock: new shares = 2520 / 40 // = 63.0M -> pro forma shares = 313.0M // Pro forma EPS before synergies = 620 / 313 // = $1.981 ``` Dilution = $1.981 / $2.00 − 1 = **(1.0%)**. To break even, pro forma net income must rise to the level that restores $2.00 EPS: ```excel // Net income needed for breakeven = Standalone_EPS * Pro_Forma_Shares = 2.00 * 313 // = $626.0M // After-tax shortfall = 626.0 - 620.0 // = $6.0M // Pre-tax synergies required (gross up for tax) = 6.0 / (1 - Tax_Rate) = 6.0 / 0.75 // = $8.0M ``` So just **$8M of pre-tax synergies** flips this deal from dilutive to neutral; anything above that is accretive. Framing the answer this way ("we need only $8M of the $50M synergy plan to break even") is far more persuasive in an investment committee than a bare "the deal is 1% dilutive." --- ## Sensitivity: Premium vs Financing Mix A single accretion number is fragile - it moves with both the premium paid and the financing mix. Build a two-way table (all figures = accretion / (dilution) %, no synergies) to see the whole surface at once: | Premium \ Stock % | 0% (all cash) | 50% | 100% (all stock) | | :--- | :---: | :---: | :---: | | 10% | +6.2% | +4.7% | +3.5% | | 20% | +4.6% | +3.1% | +2.0% | | 30% | +2.9% | +1.6% | +0.5% | | 40% | +1.3% | +0.1% | (1.0%) | Two patterns jump out. First, **moving down a column** (higher premium) always reduces accretion - you are paying more for the same earnings. Second, **moving left across a row** (more cash, less stock) always *increases* accretion here, because cheap after-tax debt beats issuing 20.0x-multiple equity. The all-cash column never goes dilutive in this deal, while the all-stock column tips negative once the premium pushes the P/E paid above BuyCo's own 20.0x - which happens at exactly a 33% premium ($40.00 offer, 20.0x paid). That breakeven premium is the same rule of thumb from the top of the article, now visible as the zero-crossing in the grid. The full M&A model below lets you flex these inputs - premium, financing mix, synergies, interest rate - and watch pro forma EPS update live. --- ## Accretive Does Not Mean Value-Creating This is the single most important caveat, and the one most often missed. EPS accretion is an *accounting* outcome, not an *economic* one: - A deal financed entirely with cheap debt will look accretive almost regardless of whether the target is a good business - low after-tax interest cost mechanically lifts combined EPS. - A high-growth target acquired in stock can be dilutive in Year 1 yet create enormous value as its earnings compound - Amazon and many software roll-ups have run exactly this playbook. - Accretion ignores the **risk** added to the combined entity: more leverage, integration risk, and a higher cost of equity that the EPS number never sees. Use accretion / dilution as a *communication and screening* tool, not a *valuation* tool. For the actual go / no-go decision, lean on a [DCF and the full suite of valuation methods](/blog/business-valuation-methods), and remember the distinction between [enterprise value and equity value](/blog/enterprise-value-vs-equity-value) when you translate an offer price into funding needs. The same pro forma debt-and-EPS mechanics also sit at the heart of an [LBO model](/blog/lbo-model-tutorial), where returns - not EPS - are the scorecard. --- ## Common Mistakes to Avoid 1. **Treating accretion as value creation.** The cardinal sin. An accretive deal can destroy value and a dilutive one can create it. Always pair the EPS read with a real valuation. 2. **Forgetting the after-tax adjustment.** Interest on new debt, foregone interest on cash, and synergies all hit *after* tax. Modeling them pre-tax overstates the EPS impact by the full tax rate. 3. **Ignoring foregone interest on balance-sheet cash.** If the deal is funded with existing cash rather than new debt, you still lose the interest income that cash was earning - a real cost to pro forma net income. 4. **Omitting incremental D&A from the write-up.** Purchase accounting steps up acquired assets and intangibles, creating extra depreciation and amortisation that reduces pro forma earnings. Skipping it flatters the result. 5. **Pricing new shares at the wrong number.** Shares issued in a stock deal are valued at the acquirer's *market* price, not book value or par. Using the wrong price misstates the new share count and the whole denominator. 6. **Double-counting or front-loading synergies.** Synergies rarely arrive in full on day one. Phasing them in (and netting integration costs) keeps the Year-1 accretion honest. 7. **Forgetting transaction and financing fees.** Advisory, financing, and other deal costs reduce earnings or equity. Leaving them out is a small but persistent source of over-optimism. --- ## Key Takeaways - **The whole analysis is one ratio:** pro forma EPS ÷ standalone acquirer EPS − 1. Everything else is about building pro forma net income and pro forma shares correctly. - **The P/E rule of thumb predicts the direction** of an all-stock deal: accretive when the acquirer's P/E exceeds the P/E paid (premium included), dilutive when it's lower. - **Financing choice usually dominates.** Cheap after-tax debt makes cash deals more accretive than the same deal in stock; issuing equity at a low earnings yield is the costliest way to pay. - **Synergies are decisive and dangerous.** They can flip a dilutive headline to accretive - which is exactly why breakeven synergy analysis ("how much do we actually need?") is the most persuasive number in the deck. - **Sensitivity beats a point estimate.** A premium-by-financing-mix grid shows where the deal tips from accretive to dilutive and how much cushion you have. - **Accretive is not the same as value-creating.** Use accretion / dilution to screen and communicate; use DCF, comps, and returns analysis to actually decide. Ready to run your own deal? Start with the [M&A Modeling & Valuation template](/templates/ma) - it pairs the accretion / dilution engine with DCF, comps, and precedent transactions so you can pressure-test both the EPS optics and the underlying economics in one workbook. ## Frequently asked questions ### What does accretion / dilution mean in M&A? Accretion / dilution measures whether an acquisition raises or lowers the acquirer's earnings per share (EPS). If the combined company's pro forma EPS is higher than the acquirer's standalone EPS, the deal is accretive; if it's lower, the deal is dilutive; if equal, it's breakeven. It is a quick, widely-watched test of a deal's near-term EPS impact, but it reflects accounting optics rather than true economic value creation. ### How do you calculate whether a deal is accretive or dilutive? Compute pro forma net income (acquirer net income + target net income + after-tax synergies, minus after-tax interest on new debt, foregone interest on cash used, and any incremental depreciation/amortisation from asset write-ups), then divide by pro forma diluted shares (acquirer shares + any new shares issued in a stock deal). Divide pro forma net income by pro forma shares to get pro forma EPS, then compute pro forma EPS / standalone acquirer EPS - 1. A positive number is accretion; negative is dilution. ### What is the P/E rule of thumb for accretion / dilution? For a 100% stock deal, compare the acquirer's P/E to the P/E it pays for the target (offer value divided by target net income, which includes the premium). If the acquirer's P/E is higher than the P/E paid, the deal is accretive; if lower, it's dilutive; if equal, breakeven. The logic: the acquirer issues equity valued at its own P/E to buy earnings at the P/E paid, so buying earnings more cheaply than its stock is valued lifts EPS. Cash deals instead compare the target's earnings yield to the after-tax cost of the cash or debt. ### Does an accretive deal always create value? No. EPS accretion is an accounting outcome, not an economic one. A deal funded with cheap debt can look accretive even if the target is a mediocre business, because low after-tax interest mechanically lifts combined EPS. Conversely, a high-growth target bought in stock can be dilutive in Year 1 yet create substantial long-term value. Accretion also ignores the added leverage, integration risk, and higher cost of equity the combined company takes on. Use accretion / dilution to screen and communicate, and use DCF and comparable analysis to judge value. ### How do synergies affect accretion / dilution? Synergies (cost savings or revenue gains from combining the businesses) are added to pro forma net income on an after-tax basis, so $50M of pre-tax synergies at a 25% tax rate adds $37.5M to pro forma earnings. Synergies frequently turn a dilutive deal accretive, which is why they receive heavy scrutiny. A deal that only works with large, unproven synergies is a warning sign. Best practice is to phase synergies in over time and net out the integration costs needed to achieve them. ### What is breakeven analysis in an accretion / dilution model? Breakeven analysis calculates how much pre-tax synergy is required to lift a dilutive deal's pro forma EPS back to the acquirer's standalone EPS. Compute the pro forma net income needed for breakeven (standalone EPS times pro forma shares), subtract the pro forma net income before synergies to get the after-tax shortfall, then divide by (1 - tax rate) to gross it up to a pre-tax figure. Expressing the result as 'we only need $8M of our $50M synergy plan to break even' is far more persuasive in an investment committee than simply stating the deal is 1% dilutive.